Glucagon-like peptide-1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.

/in /by

A.E. Hogan, G. Gaoatswe, L. Lynch, M. Corrigan, C. Woods, J. O’Connell and D. O’Shea. Glucagon-like peptide-1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetalogica 2014; 57(4):781-4. | PubMed